1C
PTCT icon

1623 Capital’s PTC Therapeutics PTCT Stock Holding History

1623 Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,335
Closed -$334K – 46
2022
Q2 		$334K Buy
+8,335
New +$292K 0.21% 41
2021
Q4 		– Sell
-16,000
Closed -$595K – 69
2021
Q3 		$595K Buy
16,000
+2,538
+19% +$104K 0.23% 46
2021
Q2 		$569K Buy
+13,462
New +$577K 0.22% 46

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

1623 Capital's PTCT Position: Q3 2022 in Review

1623 Capital sold out of PTC Therapeutics (PTCT) in Q3 2022, closing a stake of 8,335 shares — an estimated $334K sold.

1623 Capital first reported a position in PTCT in Q2 2021 and held it in 3 quarters. The position peaked at $595K in Q3 2021. 213 funds tracked by Wall St. Rank hold PTCT as of Q3 2022.

  • 1623 Capital reported no remaining PTC Therapeutics position as of Q3 2022 after selling out during the quarter.
  • 1623 Capital sold 8,335 PTC Therapeutics shares in Q3 2022, an estimated $334K.
  • 1623 Capital first reported a position in PTC Therapeutics in Q2 2021 and held it in 3 quarters.
  • 1623 Capital's PTC Therapeutics position peaked at $595K in Q3 2021.
  • 213 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2022.

Based on 1623 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.